Cruz HBR Registry - Post-market Registry to Evaluate the Safety and Efficacy of the Supraflex Cruz Stent

CompletedOBSERVATIONAL
Enrollment

1,200

Participants

Timeline

Start Date

February 19, 2020

Primary Completion Date

May 31, 2022

Study Completion Date

May 31, 2022

Conditions
Coronary Artery Disease
Interventions
DEVICE

Supraflex Cruz Sirolimus-eluting Stent

Patient implanted with at least one Supraflex Cruz sirolimus-eluting stent as a part of planned clinical care

Trial Locations (26)

1700

University and Hospital Fribourg, Fribourg

8091

University Hospital Zurich, Zurich

9000

Kantonsspital St. Gallen, Sankt Gallen

10117

Charité Campus Mitte, Berlin

12203

Charité Campus Benjamin Franklin, Berlin

13353

Charité Campus Virchow, Berlin

23795

Segeberg Kliniken, Bad Segeberg

24105

UKSH, Kiel

26389

Klinikum Wilhelmshaven, Wilhelmshaven

31059

CHU de Toulouse - Rangueil, Toulouse

32545

Heart and Diabetes Center Nordrhine Westfalia, Bad Oeynhausen

34295

CHRU de Montpellier, Montpellier

35392

University Hospital Erlangen, Erlangen

41464

Städtische Kliniken Neuss, Lukaskrankenhaus, Neuss

44137

St Johannes Hospital, Dortmund

45138

Elizabeth Krankenhaus, Essen

61231

Kerckhoff Heart Center, Bad Nauheim

67500

Centre Hospitalier Haguenau, Haguenau

76000

Clinique Saint Hilaire, Rouen

91300

Hôpital Privé Jacques Cartier, Massy

91480

Hôpital Privé Claude Galien, Quincy-sous-Sénart

93053

Universitätsklinikum, Regensburg

99089

HELIOS Klinikum Erfurt, Erfurt

01307

Herzzentrum Dresden - Universitätklinikum an der TU Dresden, Dresden

Unknown

Praxisklinik Dresden, Dresden

04289

Universität Leipzig - Herzzentrum, Leipzig

All Listed Sponsors
collaborator

European Cardiovascular Research Center

NETWORK

lead

Sahajanand Medical Technologies Limited

INDUSTRY

NCT04138238 - Cruz HBR Registry - Post-market Registry to Evaluate the Safety and Efficacy of the Supraflex Cruz Stent | Biotech Hunter | Biotech Hunter